For the quarter ending 2025-09-30, XOMAO had $52,068K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Income and revenues | 9,351 | - |
| Business development and deal related costs | 10,085 | - |
| Research and development expenses | 2,793 | - |
| Depreciation of property and equipment | 14 | - |
| Other general and administrative expenses | 31,531 | - |
| Amortization of intangible assets | 3,276 | - |
| Gains on acquisitions | 18,004 | - |
| Change in fair value of derivatives related to castle creek | -15 | - |
| Interest expense | 16,707 | - |
| Other income, net-Operating Segments | 8,466 | - |
| Income tax expense | 49 | - |
| Net income (loss) | 14,051 | 11,558 |
| Adjustment for income from eir method purchased receivables | 4,562 | -3,935 |
| Stock-based compensation expense | 1,770 | 3,588 |
| Gains on acquisitions | 18,004 | - |
| Gain on sale of equity securities | -1,510 | 5,173 |
| Income tax expense | 49 | - |
| Common stock contribution to 401 | 0 | 141 |
| Amortization of intangible assets | 878 | 1,199 |
| Depreciation | 2 | 6 |
| Accretion of long-term debt discount and debt issuance costs | 387 | 749 |
| Non-cash lease expense | -16 | -31 |
| Change in fair value of equity securities | 1,230 | - |
| Change in fair value of available-for-sale debt securities classified as cash equivalents | 0 | 49 |
| Change in fair value of derivatives | -15 | 5 |
| Trade and other receivables, net | 1,209 | -22 |
| Prepaid expenses and other assets | -124 | -1,715 |
| Accounts payable and accrued liabilities | -2,861 | -387 |
| Operating lease liabilities | -49 | -219 |
| Unearned revenue recognized under units-of-revenue method | -307 | -671 |
| Net cash provided by (used in) operating activities | -296 | 8,668 |
| Net cash, cash equivalents, and restricted cash acquired in acquisition-Turnstone Biologics Corp | 3,943 | - |
| Net cash, cash equivalents, and restricted cash acquired in acquisition-Hillevax Inc | 46,832 | - |
| Payments of consideration under rpas, aaas, and cppas | 0 | 8,000 |
| Receipts under rpas, aaas, and cppas | 1,100 | 2,039 |
| Payment for bioinvent contract-based intangible asset | 111 | 20,614 |
| Payment of contingent consideration related to kinnate ip asset | 550 | - |
| Purchase of equity securities | 0 | 99 |
| Sale of equity securities | 6,999 | - |
| Net cash provided by investing activities | 58,213 | -26,674 |
| Principal payments - debt | 5,533 | 5,065 |
| Debt issuance costs and loan fees paid in connection with long-term debt | 0 | 80 |
| Payment of preferred stock dividends | 1,368 | 2,736 |
| Repurchases of common stock | 25 | 2,370 |
| Proceeds from exercise of options and other share-based compensation | 2,526 | 896 |
| Taxes paid related to net share settlement of equity awards | 1,449 | 570 |
| Net cash used in financing activities | -5,849 | -9,925 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 52,068 | -27,931 |
| Cash and cash equivalents at beginning of period | 106,416 | - |
| Cash and cash equivalents at end of period | 130,553 | - |
XOMA Royalty Corp (XOMAO)
XOMA Royalty Corp (XOMAO)